Gilead Sciences, Inc.: GILD Could Squeeze the Bears From Here

Gilead Sciences enjoyed a rally Monday along with the rest of the biotech sector. This breakout could be followed up by a short squeeze in GILD stock. More 

The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is a Buy, But Not for Long

The iShares Nasdaq Biotechnology ETF (IBB) has yet to pull off something that other parts of the market have -- and that spells opportunity in IBB. More 

Gilead Sciences, Inc.: Short the Looming Value Trap in GILD Stock

GILD stock is looking ripe for the picking in biotech market that appears to be seeing a bounce, but Gilead is a value trap waiting to snap. More 

2 Drug Stocks To Buy For Safe Dividends And 20% Gains

With all the talk on the campaign trail about drug costs, it's safe to say the pharmaceutical industry is under siege. But these drug stocks are solid buys More 

62 Stock Upgrades (and Downgrades) for the Week

During these time it pays to stay on top of the latest profit opportunities. Today's blog post is be a great place to start with these 62 trades to make More 

Thursday’s Vital Data: Bank of America Corp (BAC), Gilead Sciences, Inc. (GILD) and Kinder Morgan Inc (KMI)

Bank of America (BAC) call options soar on strong consumer credit, Gilead’s (GILD) Harvoni gets a new FDA indication and Kinder Morgan (KMI) is bolstered by Buffett. More 

Trade of the Day: Oversold GILD Stock Offers Good Risk/Reward Setup

Traders have the chance to play a sharp bounce in Gilead Sciences, Inc. More